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Abstract
Purpose The aim of the study was to assess sentinel lymph
node biopsy (SLNB) results in colon cancer (CC) regarding
basic anthropometric features of the studied population and
their derivatives calculated using mathematical formulas.
Methods One hundred three SLNBs in CC have been
analysed. Various indicators were calculated for every patient
using mathematical formulas: BMI, Roher’si n d e x ,l e a nb o d y
weight, body fat percentage and body weight/ideal body
weight for a given height ratios using the following formulas:
Broca’s, Broca’s ideal weight, Broca–Brugsch, Lorenz’s,
Potton’s, Devine’s, Robinson’s, Miller’s and Hamwi. The
results were compared with accuracy, sensitivity and false
negative results percentage by means of ROC curves and the
test for structure indicators (for determined cut-off points).
Results No statistically significant relationship between the
results and patients' sex or age were found. ROC curve
analysis did not reveal statistically significant relationships
between the obtained results and indicators calculated on the
basis of growth and weigh (all p>0.05). The analyses of
sensitivity and accuracy with determined cut-off point, in
spite of differences amounting to 19 % (analysis of lean
body weight/weight ratio), showed no statistical signifi-
cance for any of the relationships (all p>0.05).
Conclusions No indicator with high diagnostic and prog-
nostic value has been found. The problem of qualifying
patients for SLNB in CC in regard of the anthropometric
features of the population and body composition assessment
formulas remains open and requires further analysis on
larger populations.
Keywords Sentinelnodebiopsy.Coloncancer.
Anthropometricfeatures.BMI.Bodycomposition
Introduction
The most important prognostic factor in the colorectal can-
cer (CRC) is the local lymphoid system’s status. Lymph
node (LN) metastasis lowers 5-year survival rate from 70–
90 % to 40–60 % [1–6]. In case of colon cancer (CC)
regional lymphoid system involvement decides patient’s
eligibility for adjuvant therapy, chemotherapy significantly
improves survival rate [2, 6–11]. Up to 30 % of the after
surgery pN0 patients will die within 5 years due to local
recurrence or remote metastasis [3, 6–13]. As a result, it
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that potentially may benefit from adjuvant therapy [1, 3, 7,
8, 14, 15]. Presently, the improvement of diagnosing the
LNs seems essential. The sentinel lymph node biopsy
(SLNB) in CC enables examination of the first nodal station
of the lymphatic drainage from the tumour. Precise exami-
nation of these LNs using serial tissue slicing, immunohis-
tochemical staining (IHC) and reverse transcription
polymerase chain reaction may potentially upstage lym-
phoid system status compared to the results achieved using
haematoxylin and eosin staining (H&E) [3–13, 16, 17]. It
needs to be stressed that an en block resection of the tumour
with a margin of healthy tissue and mesocolon remains the
standard treatment. Recent suggestions to implement SLNB
as a mesocolon-sparing treatment during laparoscopic pro-
cedures constitute a separate issue [5, 11, 17–19].
Presently, with the ongoing dispute whether to perform
SLNB in CC, there’s a need to determine the group of
patients who will benefit from it maximally. Qualifying
patients means, on one hand, fulfilling certain eligibility
criteria and, on the other hand, the issue of stating measur-
able indicators whether the procedure is legitimate for a
given group of patients. Available literature doesn't provide
a consensus on qualifying patients regarding basic anthro-
pometric features, such as height, weight and possible deriv-
atives such as Body Mass Index (BMI). Data from papers on
SLNB in diseases where it’s a standard procedure (breast
cancer, melanoma) suggest there’s a relation between BMI
and efficacy and sensitivity of the procedure [20–25]. Ana-
logically, it’s claimed that intra-abdominal obesity may
cause difficulties in identifying dyed LNs in the mesocolon.
Consequently, it may induce mistakes during the procedure,
lowering detection rates or increasing the number of false
negative results. This problem affects the most important
trend, i.e. SLNB as an extra diagnostic tool for patients with
negative H&E staining results of LNs [19, 26, 27]. It’s also
influencing the perspectives of using lymph node mapping
(LNM) as a mesocolon-sparing treatment.
The aim of this work is to analyse the results of SLNB in
CC in regard of basic anthropometric features of the studied
population and their derivatives calculated with mathemat-
ical formulas. These features may potentially allow assess-
ment of the intra-abdominal obesity and the risk of excessive
mesocolon adipose tissue.
Materials and methods
One hundred three SLNBs in CC have been performed in
the 1st Clinic of Surgical Oncology and General Surgery,
Wielkopolska Cancer Centre during the period of time from
May, 2005 till November, 2010. The studied group con-
sisted of 48 men and 55 women, median age 65 (IQR 56–
70). Division of patients according to cancer stage without
taking into consideration the IHC examination of sentinel
lymph nodes (SLNs) (according to AJCC Cancer Staging
Manual, Seventh Edition 2010) is presented in Table 1.
The criteria of eligibility for the study were: histopatholog-
ically confirmed and resectable colon cancer, patient’s age over
18 years old, good overall physical status (ASA I-III), no prior
colon or mesocolon surgeries (including appendectomy in case
of tumours of the right side of the colon). Patients with intra-
operativelyassessedsuspiciousLNs,locallyadvancedtumours,
distantmetastases,synchronisedneoplasmsandoperateddueto
emergency indications (intestinal obstruction) were excluded
from the study. All the procedures were open surgeries. Each
SNLB was performed by a surgical team including a surgeon
who has completed at least ten procedures of this type.
After opening the abdomen in the large intestine, fragment
that was to be removed was delicately mobilised in each case.
Subserosally, 2–4 ml of Patent Blue dye was administered by
four injections. Then pigmentation of lymph vessels and
nodes was observed, and sentinel nodes were defined as the
first nodes pigmented after 5–10 min from dye application.
SLNs were marked with a suture to be subsequently sent for
analysis (during or after the procedure) while a standard en
block resection of the tumour with a margin of healthy tissue
and mesocolon lymphoid system was completed.
Specimen collected during the operation was fixated in a
standard way, embedded in paraffin and stained with H&E.
If no macrometastases were present, the multisectioning was
used for processing the SLNs. The material was cut into
sections of the thickness of 250 μm. On each of the obtained
Table 1 Division of material with respect to cancer staging according
to the TNM, Classification of Malignant Tumours by Dukes and
Dukes, modified by Astler and Coller (in accordance with AJCC
Cancer Staging Manual, Seventh Edition 2010)
Stage T N M Dukes MAC Patients (%)
0 Tis N0 M0 –– 2 (1.9%)
I T1 N0 M0 A A 6 (5.8%)
T2 N0 M0 A B1 15 (14.6%)
IIA T3 N0 M0 B B2 50 (48.5%)
IIIA T2 N1a M0 C C1 1 (1.0%)
T2 N1b M0 C C1 1 (1.0%)
IIIB T2 N2a M0 C C1 2 (1.9%)
T2 N2b M0 C C1 1 (1.0%)
T3 N1a M0 C C2 9 ( 8.7%)
T3 N1b M0 C C2 7 (6.8%)
T3 N2a M0 C C2 5 (4.9%)
IIIC T3 N2b M0 C C2 3 (2.9%)
T4a N2a M0 C C2 1 (1.0%)
T tumour, N nodes, M metastasis, Dukes Dukes staging system, MAC
Dukes, modified by Astler and Coller, staging system
780 Langenbecks Arch Surg (2012) 397:779–786levels, at least four sections of 5-μm thickness were stained
immunohistochemically (CKMNF116 (Code: M 0821),
CKAE1/AE3 (Code: M 3515) monoclonal antibodies,
DAKO company, CAM 5,2 (No. 345779) monoclonal anti-
bodies, Becton Dickinson).
SLN was qualified as positive if there was a positive
result in H&E staining and if there were micrometastases
(foci of cancer cells 0.2–2 mm in diameter) in IHC. LNs
containing isolated cancer cells (foci of cells <0.2 mm in
diameter) or single cells positive in cytokeratin stain were
classified as negative.
To assess efficacy and quality of the procedure, levels of
detection, sensitivity and accuracy were calculated. Upstaging,
falsepositiveresultsandthenegativepredictivevaluewerealso
calculated. Subsequently, the results were compared to age and
sexof thepatients.BMIwascalculatedforeverypatientusinga
formula:BMI ¼
body weight in kg
height in m ðÞ
2 ; Roher’s index using a formula:
Roher0s index ¼
body weight in kg
height in m ðÞ
3 ; lean body weight using formu-
las:Lean Body Weight for men ¼ 1:2   body weight in kg ðÞ
 128
body weight in kg ðÞ
2
100 height in m ðÞ
2

; Lean Body Weight for women ¼
1:07   body weight in kg ðÞ   148
body weight in kg ðÞ
2
100  height in m ðÞ
2

; Body
Fat Percentage using a formula: Body Fat %01.2×BMI+
0.23×age in years−10.8×(sex; M01,F00)−5.4. Body weight
for a given height was calculated using Broca’s index: proper
weight0height in cm−100; Broca’s formula for ideal weight:
ideal weight F00.85×(height in cm−100), ideal weight M0
0.9×(height in cm−100); Broca–Brugsch formula: ideal
weight0height in cm−100 (for height 155–164 cm) or ideal
weight0height in cm−105 (for height 165–175 cm) or ideal
weight0height in cm−110 (for height 176–190 cm); Lorentz
formula for height ≥150 cm: proper weight0height in
cm−100−0.25×(height in cm−150); Potton’sf o r m u l a :
proper weight M ¼ height in cm   100  
height in cm 100
20

;
proper weight F ¼ height in cm   100  
height in cm 100
10

.W e
also calculated body weight using formulas known in drugs
dosage calculations: Devine’s formula: ideal weight M050+
2.3 kg for every inch over 5 ft, ideal weight F045.5+2.3 kg for
every inch over 5 ft; Robinson’s formula: ideal weight M052+
1.9 kg for every inch over 5 ft, ideal weight for women049+
1 . 7k gf o re v e r yi n c ho v e r5f t ;M i l l e r ’s formula: ideal weight
M056.2+1.41 kg for every inch over 5 ft, ideal weight F0
53.1+1.36 kg for every inch over 5 ft; Hamwi formula: ideal
weight M048+2.7 kg for every inch over 5 ft, ideal weight F0
45.5+2.2 kg for every inch over 5 ft. The result from every
weight formula was matched to patient’s current weight: cur-
rent weight/ideal weight according to a given formula.
Results for each sex were analysed using chi-square test,
for every variable depending on sex, age, mass and height,
ROC graphs were plotted to find cut-off points for sensitiv-
ity, accuracy, and false negative results percentage in SLNB
in CC. Additionally, cut-off points were determined for
particular calculated parameters: for BMI, 23 and 25; for
lean body weight, 0.72; for body fat percentage, 28 %; for
all the ratios current weight/ideal weight for a given height,
1. The obtained results were analysed in terms of method
sensitivity and accuracy, each single time comparing two
groups on the both sides of a cut-off point with the use of the
test for structure indicators.
The study has been approved by the Bioethics Commis-
sion of Poznan University of Medical Sciences.
Results
In an average specimen, 14.3 LNs were analysed (median
13, IQR 9.75–18). In 66 % (68) of patients 12 or more LNs
were analysed. No complications during SLNB procedure
were observed and at least one SLN (median 3, IQR 2–4)
was identified in 102 out of 103 patients (99 %). After H&E
and IHC staining, the SLN was confirmed as the only place
of metastasis in 13/102 patients (12.7 %). Accuracy of SLN
in predicting the status of the local lymphatic system was
94.1 % (96/102). Sensitivity of the method in predicting the
status of the local lymphatic system was 84.2 % (32/38).
The index of false negative results was 15.8 % (6/38). In
three out of these six patients, aberrant lymphatic drainage
(ALD) was observed after administering dye; mesenteric
root LN were marked. ALD percentage was 2.9 % (3/102).
Negative predictive value was 91.4 % (64/70). In seven
patients with negative SLN after H&E staining and its
positive result in IHC stain, no tumour deposits were found
in the remaining specimen, so the upstaging due to IHC
stain was 9.9 % (7/71).
Median height in the population was 1.68 m (IQR 1.60–
1,72 m). Median body weight was 72 kg (IQR 61.5–81.25).
Median BMI was 25.64 kg/m
2 (IQR 22.63–28.33 kg/m
2).
There was no statistically significant difference in the results
regarding sex and age of the patients. In the plotted ROC
graphs, there was no significant relation for all of the indi-
cators calculated based on body weight and height. In the
studied material, height/weight ratio (area under curve—
AUC00.50, p00.4771), BMI (AUC00.53, p00.3223),
Roher’s index (AUC00.54, p00.2340), lean body weight/
weight ratio (AUC00.42, p00.9258), body fat percentage
(AUC00.57, p00.1171) and the ideal weight calculated
using Broca’s (AUC00.54, p00.2790), Broca’s ideal weight
(AUC00.54, p00.2441), Broca–Brugsch (AUC00.51, p0
0.4123), Lorenz’s (AUC00.48, p00.6153), Potton’s
(AUC00.54, p00.2494), Devine’s (AUC00.55, p0
0.2216), Robinson’s( A U C 00.55, p00.2088), Miller’s
(AUC00.53, p00.3112) and Hamwi (AUC00,56, p0
0.1651) formulas were all insignificant.
Langenbecks Arch Surg (2012) 397:779–786 781The results of sensitivity and accuracy obtained in
particular groups for the determined cut-off points are
presented in Tables 2 and 3. In spite of differences in the
sensitivity and accuracy of the method, reaching 19 %
and obtained in the calculations for the particular groups,
statistical significance was not found for any of the
parameters.
Discussion and conclusions
The influence of anthropometric factors on SLNB is treated
marginally in literature. The vast majority of available data
concerns breast cancer where mostly isotope and dye double
technique is used. Radiocolloid is used very rarely in SLNB
in CC (it migrates faster in colon LVs than in breast or
melanoma, thus increasing the probability of marking more
h o ts e n t i n e ln o d e s ;a l s o ,i d entification is harder due to
closeness of the primary tumour and the node and the
radiation overlap) [13, 26, 28–30]. Nevertheless, in view
of general study ideas and lack of reports, the problem
seems worth mentioning. In a multi-centre British study
ALMANAC [20] on SLNB in breast cancer, there was a
relation found between BMI and detection rate—the group
with BMI≤30 kg/m
2 (n0425) showed statistically higher
detection rate than the group with BMI>30 kg/m
2 (n0113)
(98.1 % vs. 87.6 %, p<0.001). The relation was not con-
firmed for the percentage of false negative results. Another
study analysing 748 SLNBs in breast cancer [21] has shown
that SLN identification failure rate was 15.9 % for patients
with BMI>27 kg/m
2, 8.5 % for patients with BMI of 22.5–
27 kg/m
2 and 7.7 % for patients with BMI<22.5 kg/m
2.
This study additionally stated that high BMI not only
reduces tissue translucency but also that excessive fat may
pressurise LV walls interfering with proper drainage. An
American study [22] analysing 2,495 SLNBs in breast can-
cer using isotope-dye technique demonstrated inverse rela-
tion between BMI and identification frequency (r0−0.98,
p00.002). This relation was statistically significant in
groups under and over 50 years old. An average BMI was
compared in groups with positive and negative identifica-
tion showing statistically significant difference (25.9 vs.
29.4, p< 0 . 0 0 1 )b o t hi ng r o u p su n d e ra n do v e r5 0y e a r s
old. A multifactorial analysis stated that age and BMI have
the most significant (inversely proportional) influence on
LNM efficacy. Similar results were obtained also in some
Table 2 Sensitivity results
obtained in particular groups for
the determined cut-off points
BMI <25 ≥25 p value
75% 91% 0.1811
<23 ≥23 p value
80% 86% 0.6534
Lean body weight/body weight ≥0.72 <0.72 p value
94% 75% 0.1107
Body Fat Percentage <28% ≥28% p value
100% 82% 0.3542
Weight/Broca weight for a given height <1.00 ≥1.00 p value
85% 84% 0.9359
Weight/ideal weight Broca <1.00 ≥1.00 p value
100% 83% 0.5244
Weight/ideal weight Broca–Brugsch <1.00 ≥1.00 p value
80% 86% 0.6534
Weight/ideal weight Loretz <1.00 ≥1.00 p value
78% 86% 0.5864
Weight/ideal weight Potton <1.00 ≥1.00 p value
86% 84% 0.8953
Weight/ideal weight Devine <1.00 ≥1.00 p value
100% 82% 0.3542
Weight/ideal weight Robinson <1.00 ≥1.00 p value
80% 85% 0.7743
Weight/ideal weight Miller <1.00 ≥1.00 p value
88% 83% 0.7314
Weight/ideal weight Hamwi <1.00 ≥1.00 p value
89% 83% 0.6646
782 Langenbecks Arch Surg (2012) 397:779–786other studies on the relationship between the results of
sentinel node biopsy in breast cancer and BMI [23–25].
Currently, there are only a few available studies on qual-
ifying patients for SLNB in CC. There weren’t any satisfac-
tory attempts to discuss qualifying patients for the procedure
in regard of anthropometric features. Both a meta-analysis
by Des Guetz et al. [4], a review article by Bembenek et al.
[28] and the most recent meta-analysis by van der Pas et al.
[31] do not raise the problem of qualification of patients in
terms of anthropometric features. The issue has been
addressed in a work by Cahill et al. [19]—the authors found
d a t ao nB M Io n l yi nf o u rp a p e r si n c l u d e di nt h em e t a -
analysis. A relationship between high BMI and intra-
abdominal obesity has been potentially determined as a
factor that disrupts mesocolon translucency, hinders identi-
fication and increases false negative results rate in SLNB in
CRC and, additionally, that causes difficulties for a surgeon.
Some of the studies available for in-vivo mapping are men-
tioned in Table 4. They utilise simplest derivatives of height
and weight, both of which are practically always measured
on admittance. The question remains whether BMI is a good
representation of intra-abdominal obesity which possibly
may interfere with identifying marked LNs in the mesocolon.
Undoubtedly, excessive adipose tissue in the mesocolon po-
tentially causes mistakes during the procedure, i.e. lowers
detection rates or increases number of false negative results.
Thisconclusionis, however, based onthe authors' experience,
not EBM data.
In the study of Thomas et al. [32], an assumption was
made that thickened mesocolon containing excessive adi-
pose tissue may impede with identifying LNs. An obligatory
division of patients into groups was made in the analysis,
based on calculated BMI: underweight patients, BMI<
18.5 kg/m
2; normal weight patients, BMI 18.5–24.9 kg/
m
2; overweight patients, BMI 25–29.9 kg/m
2; obese
patients, BMI>30 kg/m
2. In the group of 61 (out of 69
included in the study), there was no statistically significant
difference found in precision of LNM nor the number of
false negative results comparing the group of underweight
patients and those with normal weight with the group of
overweight and obese patients. It was concluded that BMI
alone does not inform about body fat distribution—patients
with the same BMI may have different amounts of meso-
colon fat.
Another study [33] analysed 31 patients with average BMI
of 25.3 kg/m
2 (19.5–38.3). There were no statistically
Table 3 Accuracy results
obtained in particular groups for
the determined cut-off points
BMI <25 ≥25 p value
91% 96% 0.2987
<23 ≥23 p value
93% 95% 0.6938
Lean body weight/body weight ≥0.72 <0.72 p value
98% 92% 0.1919
Body Fat Percentage <28% ≥28% p value
100% 93% 0.2153
Weight/Broca weight for a given height <1.00 ≥1.00 p value
95% 93% 0.6812
Weight/ideal weight Broca <1.00 ≥1.00 p value
100% 94% 0.476
Weight/ideal weight Broca–Brugsch <1.00 ≥1.00 p value
92% 95% 0.571
Weight/ideal weight Loretz <1.00 ≥1.00 p value
91% 95% 0.4738
Weight/ideal weight Potton <1.00 ≥1.00 p value
94% 94 % 1
Weight/ideal weight Devine <1.00 ≥1.00 p value
100% 93% 0.3648
Weight/ideal weight Robinson <1.00 ≥1.00 p value
92% 94% 0.7809
Weight/ideal weight Miller <1.00 ≥1.00 p value
96% 94% 0.7077
Weight/ideal weight Hamwi <1.00 ≥1.00 p value
96% 93% 0.585
Langenbecks Arch Surg (2012) 397:779–786 783significant differences in BMI found between groups
with positive and negative identification of SLN. In
the study of Tiffet et al. [26], an assumption was made
that obesity determined by BMI is a potential reason of
detection failure. However, there was no statistically
significant relation between detection rates and patients'
BMI. It was determined that sensitivity was higher (53 % vs.
40 %) and false negative results percentage lower (18 % vs.
33 %) in patients with BMI<30 kg/m
2, but no statistical
significance was shown.
A study by Cahill et al. [18] that examined the available
databasesfromamulti-centreGermanstudy[27]andmaterial
by Saha et al. [8], analysed in detail the results of SLNB for
early changes—T1 and T2. The relationship between sensi-
tivityandBMIwasanalysedbothwiththeuseofROCandthe
arbitrary cut-off point—24 kg/m
2. No statistically significant
relationship was demonstrated in any of the analyses. How-
ever, it is emphasised in the Discussion section that including
BMI in the exclusion criteria, hypothetically, is one of the
ways of increasing the procedure sensitivity.
Similarly to the four above-mentioned studies, our re-
search in ROC analysis did not show any relation between
BMI and SLNB in CC results. Also, in the analyses con-
ducted for arbitrary cut-off points (BMI of 23 and 25), no
statistically significant relationships were found; what may
be found puzzling is that better results for sensitivity and
accuracy were obtained for the patients with higher BMI.
In a multi-centre German study [27], the examined
population consisted of 315 patients. It concluded that a
statistically higher detection rate was achieved in a
group with BMI≤25 kg/m
2 as compared to the group
with BMI>25 kg/m
2 (92.5 % vs. 80 %, p00.003).
Additionally, it was proven for the examined population
that there is a statistically significant inverse relation
between BMI and sensitivity (p00.009). This relation
was found in ROC graph analysis comparing groups
with BMI≤24 kg/m
2 (sensitivity 80 %) and BMI>
24 kg/m
2 (sensitivity 42 %) (p<0.0001).Furthermore,itwas
observed that SLNB in patients with BMI ≤24 kg/m
2 con-
ducted in centres with more experience, the sensitivity was as
high as 88 %. The summary underlined LVs visualisation
problem in obese patients and the influence of BMI on
achieved SLNB results.
In summary, our research has not proved any statis-
tically significant indicator to have high diagnostic and
prognostic value. There was no statistical significance
shown for BMI—value which is most frequently exam-
ined. Also, we failed to demonstrate significance of any
other indicator in spite of differences in the sensitivity
and accuracy of lymphatic mapping, running into 19 %
for some parameters. Thus, the problem of qualifying
patients for SLNB in CC remains open and requires
further analysis on larger populations.
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